title: Pilot study of erlotinib in patients with acute myeloid leukemia.
abstract: We conducted a pilot study to investigate clinical efficacy of tyrosine kinase inhibitor erlotinib in the treatment of acute myeloid leukemia (AML). A total of 11 patients with de novo AML were treated, including 2 with relapsed and/or refractory disease and 9 older patients with previously untreated AML. Patients with high baseline leukocyte count were excluded. Erlotinib was given orally at 150 mg per day continuously in 28-day cycles. The treatment was tolerated well, and no toxicities were observed. An initial reduction in circulating blasts, followed by disease progression, was observed in 2 patients. Nine other patients did not demonstrate any response in blood or bone marrow. Baseline and post-cycle 1 flow-cytometry were performed on bone marrow blasts to investigate signs of differentiation. No immunophenotypic changes suggestive of differentiation were observed. This pilot study did not demonstrate response to standard doses of erlotinib in patients with AML.
authors.affiliation: Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States. Electronic address: ssayar@iu.edu.
authors.forename: Hamid
authors.initials: H
authors.lastname: Sayar
authors.affiliation: Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, United States.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Czader
authors.affiliation: Hematology, Indiana Hemophilia Thrombosis Center, Indianapolis, IN, United States.
authors.forename: Chirag
authors.initials: C
authors.lastname: Amin
authors.affiliation: Hematology-Oncology, Indiana University Simon Cancer Center, Indianapolis, IN, United States.
authors.forename: Mary
authors.initials: M
authors.lastname: Cangany
authors.affiliation: Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States.
authors.forename: Heiko
authors.initials: H
authors.lastname: Konig
authors.affiliation: Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States.
authors.forename: Larry D
authors.initials: LD
authors.lastname: Cripe
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D010865:Pilot Projects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011799:Quinazolines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride
keywords: AML; Acute myeloid leukemia; EGFR; Erlotinib; Pilot study